TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS).
Save Our Seas Foundation announces Small Grants Deadline: 16-Jun-23 The Save Our Seas Foundation invites applications for small projects up to US$10,000